Trofinetide manufacturers
- Trofinetide
-
- $0.00 / 1kg
-
2025-08-22
- CAS:
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1
|
| | Trofinetide Basic information |
| Product Name: | Trofinetide | | Synonyms: | Trofinetide(NNZ2566);TROFINETIDE; NNZ2566 ;NNZ 2566; NNZ-2566;NNZ-2566;L-Glutamic acid, glycyl-2-methyl-L-prolyl-;Trofinetide;Trofinetide,NNZ 2566,NNZ2566,Inhibitor,inhibit;Glutamic acid, glycyl-;prolyl- | | CAS: | 853400-76-7 | | MF: | C13H21N3O6 | | MW: | 315.32 | | EINECS: | | | Product Categories: | API | | Mol File: | 853400-76-7.mol |  |
| | Trofinetide Chemical Properties |
| Melting point | 144 °C | | Boiling point | 655.4±55.0 °C(Predicted) | | density | 1.377±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Methanol (Slightly), Water (Slightly) | | form | Solid | | pka | 3.51±0.10(Predicted) | | color | White to Off-White | | Stability: | Hygroscopic | | InChI | InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1 | | InChIKey | BUSXWGRAOZQTEY-SDBXPKJASA-N | | SMILES | C(O)(=O)[C@H](CCC(O)=O)NC(=O)[C@]1(C)CCCN1C(=O)CN |
| | Trofinetide Usage And Synthesis |
| Uses | Trofinetide is a synthetic analogue of the endogenous N-terminus tripeptide, Glycine-Proline-Glutamate (GPE), that has shown to be neuroprotective in animal models of brain injury. | | in vivo | Trofinetide (NNZ-2566) suppresses penetrating ballistic-like brain injury (PBBI) induced inflammatory cell infiltration at 3 days following PBBI as compare to vehicle treatment. Trofinetide treatment significantly reduces the elevation of IL-6 (79%), E-selectin (81%), IL-1β (76%) and TNF-α (72%) mRNA levels in the injured hemisphere at 12 h post-PBBI, with maximal inhibition occurring between 12 h and 24 h. Trofinetide treatment does not affect the PBBI-induced up-regulation of IL-6 expression at any time point, but does produce significant reductions in the injury-induced up-regulation of IL-1β, INF-γ, and TNF-α expression. Trofinetide treatment suppresses IL-1β expression in the injured brain hemisphere for up to 7 days post-PBBI[1]. The high doses of Trofinetide (NNZ-2566) (10 and 100 mg/kg bolus followed by continuous infusion) attenuate non-convulsive seizure (NCS) occurring beyond 2 h after permanent middle cerebral artery occlusion (pMCAo). All doses of Trofinetide completely suppress the delayed occurrence of NCS as compare with the vehicle-treated animals[2]. |
| | Trofinetide Preparation Products And Raw materials |
|